Argos Therapeutics Inc (NASDAQ:ARGS) has revealed that it would be attending the Alliance for Regenerative Medicine, Cell and Gene Therapy Investor Day, due to be held on March 22, 2016. The CEO of Argos, Jeffrey D. Abbey, would be present on behalf of the company. He would provide an update on the company’s clinical development programs, to the investors. ARGS focuses on the development and commercialization of immunotherapies, based on the company’s Arcelis technology.

Most recently, the company was able to successfully reach a financing agreement, with several companies and investors, which could potentially help it, raise $60 million. An official statement from the company stated that the funds would help Argos fund operations, at least until the 2Q2017. That is also the time when the company expects to have final data from late-stage clinical trials for its lead drug.

The drug is currently known as AGS-003 and is being tested for metastatic renal cell carcinoma. Once the company has received the final results in 2Q2017, Argos can file for an FDA approval. Since Argos has yet to report its FY2015 results, its financial position can only be judged through its 3Q2015 report. As per the details of that filing, the company’s cash and cash equivalents stood at $56 million. The expected $60 million is to be received in three phases and would be in exchange for private placements and stock warrants of ARGS.

Argos CEO was a part of the moderator’s panel, during the CED Life Science’s Conference, where he had emphasized the need for biotechs to attract funding, in any way possible. During the panel discussion, he also stated that his company needed to make some innovative deals to reach where they are today. The conference was titled: “Innovative Funding and Partnership Models in Biotech”.

Argos Therapeutics Inc (NASDAQ:ARGS) reported a decline of 9.09% in share price, to reach a close at $4.90, after having a trade volume of 512,375 shares, at the end of the March 17 session.

Previous articleImmunomedics, Inc. (NASDAQ:IMMU) To Present at The Annual Meeting of American Association for Cancer Research
Next articleVitae Pharmaceuticals Inc (NASDAQ:VTAE) Increases 85.16% After Positive Result Announcement
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.